Pharmatek Announces Acquisition of Additional Xcelodose® 600S System
News Feb 07, 2013
Pharmatek has announced that it has purchased another Xcelodose® 600S system.
This acquisition doubles the company's manufacturing production rate for powder-in-capsule (PIC) operations and increases overall preclinical and early phase clinical cGMP supply capabilities.
"The acquisition of an additional Xcelodose® unit enables Pharmatek to better serve our clients' early phase development strategies and meet the growing demand for PIC projects," stated Kevin Rosenthal, Director of Manufacturing at Pharmatek.
Rosenthal continued, "For PIC applications, the Xcelodose® can drastically decrease time to clinic while also lowering the cost of drug product for first-in-human trials."
In addition to adding another Xcelodose® system, Pharmatek has implemented a dedicated Xcelodose® project team to ensure the overall success and quick turnaround of PIC programs.
Each team is led by an Xcelodose® engineer who oversees the project from planning to execution.
The Xcelodose®, manufactured by Capsugel, is a precision powder micro-doser and automated encapsulator that has the ability to fill formulations or active pharmaceutical ingredient (API) directly into capsules with a remarkable level of accuracy.
The Xcelodose® can measure to levels as low as 100 micrograms and can dispense into capsules from size 00 to 4. Dosing directly into capsules can reduce the amount of API required.
Additionally, the unit minimizes overall development time by simplifying analytical and stability protocols.
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Bone Cancer Drug Targets Tumors, Spares Other OrgansNews
A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness.READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018